NCT04792710

Brief Summary

Randomised controlled trial to investigate the efficacy of adding metronidazole pre-operatively to kefazolin in reducing postpartum infection

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Mar 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 8, 2021

Completed
Same day until next milestone

Study Start

First participant enrolled

March 8, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 11, 2021

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

March 11, 2021

Status Verified

March 1, 2021

Enrollment Period

1.1 years

First QC Date

March 8, 2021

Last Update Submit

March 8, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Efficacy of reducing surgical site infection

    Incidence of surgical site infections

    Seven days post-operatively

Secondary Outcomes (2)

  • Efficacy of reducing urinary tact infections

    Three days post-operatively

  • Efficacy of reducing postpartum endometritis

    Seven days post-operatively

Study Arms (2)

Intervention arm

EXPERIMENTAL

This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose

Drug: Metronidazole

Control arm

PLACEBO COMPARATOR

This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose

Drug: Metronidazole

Interventions

Metronidazole 500 mg intravenous stat dose prior to skin incision

Also known as: Flagyl
Control armIntervention arm

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant patients
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years and older Willing and able to provide written informed consent

You may not qualify if:

  • women younger than 18 years women not able or willing to provide written informed consent women with or without infection already receiving antibiotics for other indications women allergic to kefazolin or metronidazole

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kalafong Provincial Tertiary Hospital

Pretoria, Gauteng, South Africa

Location

MeSH Terms

Interventions

Metronidazole

Intervention Hierarchy (Ancestors)

NitroimidazolesNitro CompoundsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Leon C Snyman, PhD

CONTACT

Louisa Seopela, MMed (O&G)

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The out comes assessor will not have access to the arm the patient was randomised to.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomised placebo controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof

Study Record Dates

First Submitted

March 8, 2021

First Posted

March 11, 2021

Study Start

March 8, 2021

Primary Completion

March 31, 2022

Study Completion

June 30, 2022

Last Updated

March 11, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations